Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom

Annals of Pharmacotherapy

Volumn 40, Issue 10, 2006, Pages 1752-1758

  Jørgensen, Tine Rikke ^a   Stein, Dan J ^b   Despiegel, Nicolas ^c   Drost, Pieter B ^d   Hemels, Michiel E H ^e   Baldwin, David S ^f  

^a H LUNDBECK A S   (Denmark)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c Lundbeck   (France)

^d UTRECHT UNIVERSITY   (Netherlands)

^e Centre for Outcomes Research   (Belgium)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Cost effectiveness; Escitalopram; Paroxetine

Indexed keywords

ESCITALOPRAM; PAROXETINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; COST EFFECTIVENESS ANALYSIS; DECISION MODEL; DRUG COST; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC ASPECT; FEMALE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL LEAVE; MEDICAL SOCIETY; NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE; ORGANIZATION; OUTCOME ASSESSMENT; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROBABILITY; RELAPSE; RESOURCE MANAGEMENT; THEORETICAL MODEL; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT;

ANXIETY DISORDERS; CITALOPRAM; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; GREAT BRITAIN; HUMANS; PAROXETINE; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 33749593931     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H156     Document Type: Article

References (25)

1. Jenkins R, Lewis G, Bebbington P, et al. The National Psychiatric Morbidity surveys of Great Britain-initial findings from the household survey. Psychol Med 1997;27:775-89.
2. Lieb R, Becker E, Altamura C. The epidemiology of generalized anxiety disorder in Europe. Eur Neuropsychopharmacol 2005;15:445-52.
3. Wittchen H. Generalized anxiety disorder: prevalence, burden and cost to society. Depress Anxiety 2002;16:162-71.
4. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry Suppl 1998;34:4-9.
5. Jørgensen TR, Francois C, Despiegel N. Escitalopram treatment improves quality of life of generalised anxiety disorder patients measured by SF-36. Presented at: 12th Annual Conference of the International Society for Quality of Life Research, San Francisco, October 19-22, 2005.
6. Waugh J, Goa K. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003;17:343-62.
7. Bielski RJ, Bose A, Chang CC. A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 2005;17:65-9.
8. Davidson JR, Bose A, Korotzer A, Zheng H. Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 2004;19:234-40.
9. Goodman WK, Bose A, Wang Q. Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 2005;87:161-7.
10. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005;186:222-6.
11. NICE Clinical Guideline Anxiety. 2004. www.nice.org.uk/page.aspx?o= cg022niceguideline (accessed 2006 Jul 5).
12. Schoevers RA, Beekman AT, Deeg DJ, Jonker C, van Tilburg W. Comorbidity and risk-patterns of depression, generalised anxiety disorder and mixed anxiety-depression in later life: results from the AMSTEL study. Int J Geriatr Psychiatry 2003;18:994-1001.
13. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;9:567-96.
14. Allgulander C, Florea I, Huusom AKT. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2005;9:1-11.
15. Stocchi F, Nordera G, Jokinen RH, et al. Efficacy and tolerability of paroxetine for the long-term treatment of generalized anxiety disorder. J Clin Psychiatry 2003;64:250-8.
16. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38.
17. National Health Service England and Wales. Drug Tariff July 2005. London: Prescription Pricing Authority, 2005. www.ppa.org.uk/ppa/edt_intro. htm (accessed 2006 Jul 5).
18. Curtis L, Netten A. Unit costs of health and social care 2004. Canterbury, England: University of Kent, 2004.
19. UK National Health Service, Department of Health Homepage, Policy and Guidance. www.dh.gov.uk/Home/fs/en (accessed 2006 Jul 5).
20. Lim D, Sanderson K, Andrews G. Lost productivity among full-time workers with mental disorders. J Ment Health Policy Econ 2000;3:139-46.
21. Consumer Price Index-Health 2005. Office for National Statistics, United Kingdom. www.statistics.gov.uk (accessed 2006 Jul 5).
22. Borghi J, Guest J. Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000;15:378-87.
23. Greenberg PE, Sisitsky T, Kessler RC, et al. The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 1999;60:427-35.
24. Guest J, Russ J, Lenox-Smith A. Cost-effectiveness of venlafaxine compared with diazepam in the treatment of generalized anxiety disorder in the United Kingdom. Eur J Health Econ 2005;6:136-45.
25. United Kingdom Prime Minister's Strategy Unit: Report dated 2006 Feb 24. www.strategy.gov.uk/seminars/mental_health/index.asp (accessed 2006 Jul 5).